Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Robertson

Showing results (471-480 of 565) with videos related to

Pageof 57
Sort By:
BMJ Open|May 27, 2015
Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)M Absoud, J Gadian, J Hellier, et al.
Journal of Virology|January 18, 2008
Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccinationArumugam Balamurugan, Martha J Lewis, Christina M R Kitchen, et al.
The Journal of Sexual Medicine|July 21, 2011
Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomyMasaki Kimura, Lionel L Bañez, Florian R Schroeck, et al.
The Journal of Urology|September 18, 2009
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen erasLeon Sun, Arthur A Caire, Cary N Robertson, et al.
Cancer|February 18, 2010
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of deathToni K Choueiri, Ming-Hui Chen, Anthony V D'Amico, et al.
Plos Pathogens|July 3, 2013
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1Tomer Hertz, Hasan Ahmed, David P Friedrich, et al.
Nature Medicine|July 22, 2009
Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cellsNatalie A Hutnick, Diane G Carnathan, Sheri A Dubey, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2022
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and LamivudineJean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, et al.
Urology|October 10, 2009
Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75Arthur A Caire, Leon Sun, Cary N Robertson, et al.
BJU International|January 8, 2017
Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patientsSebastien Crouzet, Andreas Blana, Francois J Murat, et al.
Pageof 57

Showing results (471-480 of 565) with videos related to

Sort By:
Pageof 57
BMJ Open|May 27, 2015
Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE)M Absoud, J Gadian, J Hellier, et al.
Journal of Virology|January 18, 2008
Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccinationArumugam Balamurugan, Martha J Lewis, Christina M R Kitchen, et al.
The Journal of Sexual Medicine|July 21, 2011
Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomyMasaki Kimura, Lionel L Bañez, Florian R Schroeck, et al.
The Journal of Urology|September 18, 2009
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen erasLeon Sun, Arthur A Caire, Cary N Robertson, et al.
Cancer|February 18, 2010
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of deathToni K Choueiri, Ming-Hui Chen, Anthony V D'Amico, et al.
Plos Pathogens|July 3, 2013
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1Tomer Hertz, Hasan Ahmed, David P Friedrich, et al.
Nature Medicine|July 22, 2009
Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cellsNatalie A Hutnick, Diane G Carnathan, Sheri A Dubey, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2022
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and LamivudineJean-Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud, et al.
Urology|October 10, 2009
Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75Arthur A Caire, Leon Sun, Cary N Robertson, et al.
BJU International|January 8, 2017
Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patientsSebastien Crouzet, Andreas Blana, Francois J Murat, et al.
Pageof 57